Latest Solvay Group Stories
LONDON, October 22, 2012 /PRNewswire/ -- ICIS, a leading global provider of news and information for the chemical and energy sectors, today announces the winners in the ICIS Innovation Awards 2012. These annual awards are supported by Dow Corning as lead sponsor, with category sponsorship by management consultancy Roland Berger Strategy Consultants (Best Product Innovation), chemical distributor U.S. Chemicals (Innovation with Best Environmental Benefit), polymer major...
MOUNTAIN VIEW, Calif. and SAO PAULO, Aug. 1, 2012 /PRNewswire/ -- Cobalt Technologies, a leading developer of next generation bio-based chemicals and specialty chemical company Rhodia, member of the Solvay Group, today announced they will begin joint development and operation of a biobutanol demonstration facility in Brazil. This is one more step by the two companies toward the construction of commercial-scale biorefineries using Cobalt's technology to convert Brazilian bagasse...
MARIETTA, Ga., Feb. 5 /PRNewswire-FirstCall/ -- Solvay Pharmaceuticals, Inc. announced today that Phase IIIb data published in the January issue of Clinical Therapeutics confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic...
MARIETTA, Ga., Oct. 29 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. today announced that Amanda Rudd has been awarded the title of 2009 Thriving Student Achiever for her creative entry expressing her dream for the future. In honor of the 17th year of the SolvayCARES(SM) scholarship program, Amanda was awarded an educational scholarship totaling $17,000. In September, Solvay Pharmaceuticals, Inc. announced that 40 students with cystic fibrosis (CF) who are pursuing higher education had each...
MARIETTA, Ga., Oct. 26 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery. EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food and, if...
MARIETTA, Ga., Oct. 15 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that new data confirm that CREON® (pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in children aged 7-11 years who have exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF). EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food. CREON® has already...
MARIETTA, Ga., Oct. 9 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI). EPI is a condition resulting from a deficiency in the production...
ABBOTT PARK, Ill., Sept. 28 /PRNewswire-FirstCall/ -- Abbott today announced a definitive agreement with the Solvay Group for Abbott to acquire Solvay's pharmaceuticals business for EUR 4.5 billion ($6.6 billion) in cash, providing Abbott with a large and complementary portfolio of pharmaceutical products and a significant presence in key global emerging markets. The acquisition also includes full global rights to the fenofibrate franchise. Currently Abbott has U.S. rights to fenofibrate...
MARIETTA, Ga., July 7 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. today announced the commercial availability of CREON(R) (pancrelipase) Delayed-Release Capsules. Now available to be filled at pharmacies nationwide, CREON(R) was approved by the Food and Drug Administration (FDA) on April 30, 2009, for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions. CREON(R) is the first and only pancreatic enzyme product (PEP) to receive FDA...
BRUSSELS, May 18 /PRNewswire/ -- Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global codevelopment of novel biopharmaceutical product opportunities originating in China. Through this agreement, Solvay Pharmaceuticals will gain access to HUYA's comprehensive Chinese molecule portfolio, focusing specifically on compounds in the cardiovascular area. As some of these molecules are already in...
